Litigation Details for Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

Docket		Date Filed	2019-01-17
Court	District Court, D. Delaware	Date Terminated	2021-10-20
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	INTERMUNE, INC.
Patents	7,566,729; 7,635,707; 7,767,700; 7,816,383; 7,910,610; 8,013,002; 8,084,475; 8,318,780; 8,383,150; 8,420,674; 8,592,462; 8,609,701; 8,648,098; 8,754,109; 8,778,947; 9,561,217
Attorneys	Mark E. Waddell
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-01-17				External link to document
2019-01-16	1		U.S. Patent No. 7,566,729 25. U.S. Patent No. 7,566,729 (“the ‘729 patent”), entitled… U.S. Patent No. 7,767,700 29. U.S. Patent No. 7,767,700 (“the ‘700 patent”), entitled… U.S. Patent No. 8,013,002 35. U.S. Patent No. 8,013,002 (“the ‘002 patent”), entitled… U.S. Patent No. 8,383,150 41. U.S. Patent No. 8,383,150 (“the ‘150 patent”), entitled… U.S. Patent No. 8,609,701 47. U.S. Patent No. 8,609,701 (“the ‘701 patent”), entitled	External link to document
2019-01-16	18	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,566,729 B1; 7,635,707 B1; 7,767,700…2019 20 October 2021 1:19-cv-00105 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

Last updated: July 12, 2026

Litigation summary and patent analysis: Genentech, Inc. v. Aurobindo Pharma Limited, 1:19-cv-00105

Genentech, Inc. sued Aurobindo Pharma Limited in the District of Delaware under the Hatch-Waxman framework (case caption “Genentech, Inc. v. Aurobindo Pharma Limited,” 1:19-cv-00105) seeking to block FDA approval activities tied to Aurobindo’s proposed generic biosimilar/biologic product. The case is a patent infringement dispute paired with an FDA regulatory action timeline, where Genentech asserts specific Orange Book / listed patents and Aurobindo responds with non-infringement, invalidity, and/or non-jurisdictional defenses.

No litigation-capable detail (asserted patent numbers, asserted claims, procedural posture, Markman outcomes, scheduling order milestones, claim construction, trial outcomes, settlement terms, or ultimate disposition) is present in the provided record, so a complete and accurate litigation summary cannot be produced.

What patents were asserted in Genentech v. Aurobindo Pharma Limited (1:19-cv-00105)?

A complete answer requires: (1) the specific patents-in-suit (publication numbers or U.S. patent numbers), (2) which FDA-listed product they map to, and (3) the infringement theory (direct, induced, contributory; method-of-use vs formulation vs manufacture). Those elements are not included in the provided material.

What Orange Book or FDA-listed patents are implicated?

Orange Book patent identifiers and the FDA listing status (listed vs withdrawn vs expired) are needed to map infringement claims to listed protection. The underlying FDA listing and the patents-in-suit are not provided.

Which asserted claims and infringement theories matter?

A claim-by-claim summary (independent claims, dependent claims, and the alleged equivalents or structural/functional elements) requires the complaint’s claim chart or pleading-level claim detail. No such detail is available here.

When did the case start and what procedural milestones occurred in 1:19-cv-00105?

A litigation timeline requires docket dates such as: complaint filing date, summons/service completion, answer deadlines, amended pleadings, Rule 12 motions, Markman/claim construction, dispositive motions, trial or early resolution, and final judgment or dismissal. None of these dates or milestones are included.

Was there a Paragraph IV or biosimilar-style infringement trigger?

Hatch-Waxman Paragraph IV allegations hinge on the ANDA filing and certification type. For biologics, the trigger ties to biosimilar or 351(k) pathway filings and listed patents. The FDA pathway and certification type are not provided.

Were there Markman claim construction rulings?

Rulings on claim scope often drive settlement or judgment risk. Claim construction outcomes are not present.

How strong is Genentech’s patent estate in this dispute: infringement vs validity?

A strength analysis depends on: (1) the age of the asserted patents, (2) prosecution history, (3) prior art landscape, (4) claim scope post-construction, and (5) how the asserted claims map to the accused product’s composition or manufacturing process.

What invalidity grounds were raised against Genentech’s patents?

Typical grounds include anticipation, obviousness, lack of written description/enablement, indefiniteness, and patent-ineligibility. Those grounds and any PTAB activity are not provided.

Did Aurobindo argue non-infringement based on product composition or process?

Non-infringement can turn on formulation excipients, glycosylation profiles (if applicable), manufacturing method steps, or process parameters. Accused product attributes and the comparison to asserted claim elements are not provided.

What did the court do on dispositive motions?

Decisions on summary judgment motions or dismissal (Rule 12/56) are central to risk assessment. No motion outcomes are included.

What settlements or consent judgments ended Genentech v. Aurobindo (1:19-cv-00105)?

Settlement terms (payment, license scope, launch date restrictions, covenant-not-to-sue boundaries, stipulated dismissal language) must be sourced from docket entries or the settlement agreement text. No settlement information is included.

Was there a stipulated dismissal with or without prejudice?

The presence, type, and date of dismissal affect appeal and future enforcement strategy. The record provided contains no disposition.

Did the parties reach a license agreement impacting future launches?

A launch-authorization license changes generic/biosimilar risk and affects design-around strategy. No such licensing terms are included.

What generic or biosimilar entry risks existed for Aurobindo and what timeline did they face?

This requires linkage between (1) the specific FDA approval application, (2) the certification or pathway, (3) the patents-in-suit list, (4) statutory exclusivity periods (biologic exclusivity where relevant), and (5) any court-imposed stay.

When would FDA approval have been blocked or allowed?

A stay and any eventual lifting trigger depends on court outcomes and any settlement. None of those are in the provided record.

How does court timing affect “at-risk” launch exposure?

At-risk launch depends on whether the decision is final and whether infringement/validity findings block approval. Court outcomes and judgment status are not provided.

How does this dispute compare with other Genentech v. generic/biosimilar cases involving Aurobindo or similar defendants?

Comparison requires a list of related cases, their asserted patents, outcomes, and whether those outcomes influenced later settlement posture. No comparable-case data is provided.

Do similar Aurobindo disputes show recurring validity or construction themes?

Recurring themes are established by summarizing multiple disputes with the same patent family or claim construction. Not possible from the provided material.

Key Takeaways

• The case citation alone (Genentech, Inc. v. Aurobindo Pharma Limited, 1:19-cv-00105) is insufficient to produce a complete litigation summary with patent-level and procedural correctness.
• No asserted patents, FDA linkage, procedural milestones, dispositive outcomes, or settlement/disposition terms are included in the provided record.
• A defensible litigation analysis requires docket-sourced facts (complaint allegations, patents-in-suit, claim constructions, and final disposition), which are not available here.

FAQs

1. What patents are typically asserted by Genentech in Hatch-Waxman or 351(k) infringement suits against generics or biosimilars?
2. How do claim construction outcomes usually influence settlement risk in Genentech patent litigation?
3. What do courts look for when assessing non-infringement defenses against accused biologic manufacturing/process claims?
4. How does statutory exclusivity interact with stays in patent infringement cases tied to FDA approval?
5. What legal benchmarks determine whether a dismissal in a Hatch-Waxman case forecloses later launch litigation?

References (APA)

1. Case: Genentech, Inc. v. Aurobindo Pharma Limited, No. 1:19-cv-00105 (D. Del.).